Hhlr Advisors, Ltd. Legend Biotech Corp Transaction History

Hhlr Advisors, Ltd.

$3.87 Billion
Q2 2024

A detailed history of Hhlr Advisors, Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 6,636,496 shares of LEGN stock, worth $266 Million. This represents 7.6% of its overall portfolio holdings.

Number of Shares

6,636,496

Previous 5,984,550 10.89%

Holding current value

$266 Million

Previous $336 Million 12.44%

% of portfolio

7.6%

Previous 7.45%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$39.5 - $57.22 $25.8 Million - $37.3 Million	651,946 Added 10.89%	6,636,496 $294 Million
Q4 2023 Feb 14, 2024	SELL	$57.25 - $69.74 $25.9 Million - $31.5 Million	-451,983 Reduced 7.02%	5,984,550 $360 Million
Q2 2023 Aug 14, 2023	BUY	$46.28 - $75.01 $60.4 Million - $98 Million	1,306,166 Added 25.46%	6,436,533 $444 Million
Q1 2023 May 15, 2023	SELL	$43.42 - $57.37 $271,375 - $358,562	-6,250 Reduced 0.12%	5,130,367 $247 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $26.7 Million - $40 Million	700,000 Added 15.78%	5,136,617 $210 Million
Q2 2022 Aug 15, 2022	SELL	$33.54 - $55.0 $83.9 Million - $138 Million	-2,500,000 Reduced 36.04%	4,436,617 $244 Million
Q1 2022 May 16, 2022	SELL	$31.02 - $48.18 $151 Million - $235 Million	-4,868,308 Reduced 41.24%	6,936,617 $252 Million
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $30.9 Million - $42.7 Million	750,000 Added 6.78%	11,804,925 $550 Million
Q3 2021 Nov 15, 2021	BUY	$35.31 - $50.56 $367 Million - $526 Million	10,404,925 Added 1600.76%	11,054,925 $559 Million
Q2 2020 Aug 14, 2020	BUY	$36.1 - $42.56 $23.5 Million - $27.7 Million	650,000 New	650,000 $27.7 Million

Others Institutions Holding LEGN

# of Institutions

205

Shares Held

74.5M

Call Options Held

371K

Put Options Held

387K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.7B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.

Account

Hhlr Advisors, Ltd. Legend Biotech Corp Transaction History